Mutations have been shown to be more abundant in patients with metastatic disease (90%) than local disease (43%) (106), and the use of KRAS mutations to differentiate between pancreatic cancer and chronic pancreatitis has been demonstrated with ctDNA analysis at a sensitivity of 47% and specificity of 87% (104). Here, KRAS is linked to pancreatic neoplasm.